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Background: NSTEMI patients who are at are at high risk for both ischemic and bleeding events present therapeutic management challenges. 
Little is known about contemporary patterns of care across different risk profiles.
Methods: We studied 61,366 NSTEMI patients in the ACTION Registry-GWTG (AR-G) between January 2007 and March 2009. Patients were 
stratified into 4 groups based on their predicted risk (high or low as compared with the median) of both in-hospital mortality and major bleeding 
using previously validated AR-G models. Baseline characteristics and in-hospital management were compared across groups.
Results: Patients with a high predicted risk for both in-hospital mortality and bleeding events were older, more likely female, with impaired renal 
function and a prior history of MI and CHF. They were significantly less likely to receive clopidogrel, bivalirudin, and glycoprotein IIb/IIIa inhibitors or 
to undergo early catheterization, but more likely to receive excess dosing of antithrombotic therapy (p<0.001 for all).
Conclusion: About 40% of NSTEMI patients are at high risk for both adverse ischemic and bleeding events. They receive less guideline-based 
therapies for NSTEMI including medications and early catheterization yet are more likely to receive excess dosing of antithrombotic agents. 
Additional performance improvement efforts are needed to optimize outcomes in this high risk subgroup.
Table 1. Baseline characteristics and in-hospital care across AR-G risk groups. 
Low mortality and Low 
bleeding risk
(N=24,709)
Low mortality and High 
bleeding risk
(N=5,974)
High mortality and Low 
bleeding risk
(N=5,974)
High mortality and High 
bleeding risk
(N=24,709)
Age, median (IQR) 56 (49-64) 60 (53-68) 75 (69-82) 77 (70-85)
Female Sex (%) 21 70 12 55
Diabetes (%) 21 52 19 46
Prior MI (%) 22 28 29 34
Prior CHF (%) 4 12 11 31
eGFR (median,IQR) 109 (84-139) 82 (60, 108) 70 (54, 89) 46 (32, 65)
Dialysis (%) 0 0 0 7
Medications w/in 24 hrs
Aspirin (%) 98 97 97 95
Clopidogrel (%) 70 61 62 51
GP IIb/IIIa inhibitor (%) 56 43 44 26
Bivalirudin (%) 16 14 14 10
Statin (%) 64 61 62 55
Catheterization within 48 hours (%) 88 78 80 60
Excess Dosing of any heparin or GP 
IIb/IIIa inhibitor (%)
20 26 25 33
